Skip to main content
SpringerLink
Log in

Montelukast in pediatric asthma management

  • Special Article
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Leukotriene modifiers (receptor antagonist and biosynthesis inhibitor) represent the first mediator specific therapeutic option for asthma. Montelukast, a leukotriene receptor antagonist is the only such agent approved for use in pediatric patients. Montelukast modifies action of leukotrienes, which are the most potent bronchoconstrictors, by blocking Cysteinyl leukotriene receptors. Systemic drug like mountelukast can reach lower airways and improves the peripheral functions which play a crucial role in the evolution of asthma. Review of existing literature showed that montelukast compared to placebo has proven clinical efficacy in better control of day time asthma symptoms, percentage of symptom free days, need for rescue drugs and improvement in FEV1. Studies also demonstrated improvement in airway inflammation as indicated by reduction in fractional exhaled nitric oxide, a marker of inflammation. Studies comparing low dose inhaled corticosteroids (ICS) with montelukast are limited in children and conclude that it is not superior to ICS. For moderate to severe persistent asthma, montelukast has been compared with long acting beta agonists (LABA) as an add-on therapy to ICS, montelukast was less efficacious and less cost-effective. It has beneficial effects in exercise induced asthma and aspirin-sensitive asthma. Montelukast has onset of action within one hour. Patient satisfaction and compliance was better with montelukast than inhaled anti-inflammatory agents due to oral, once a day administration. The recommended doses of montelukast in asthma arechildren 1–5 years: 4 mg chewable tablet, children 6–14 years: 5mg chewable tablet, adults: 10 mg tablet; administered once daily. The drug is well tolerated. Based on the presently available data montelukast may be an alternative treatment for mild persistent asthma as monotherapy where ICS cannot be administered. It is also an alternative to LABA as an add-on therapy to ICS for moderate to severe persistent asthma. The other indications for use of montelukast include: allergic rhinitis, exercise induced bronchoconstriction and aspirin-induced asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wright AL, Taussig LM. Lessons from long term cohort studies: childhood asthma.Eur Respir J Suppl 1998; 27: 17S-22S.

    PubMed  CAS  Google Scholar 

  2. National Heart Lung and Blood Institute. NAEPP Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma-Update on Selected Topics 2002. downloaded from www.nhlbi.nih.gov/guidelines/asthma/execsumm.

  3. Global Strategy for Asthma Management and Prevention. NIH Publication No 02-3659 Issued January, 1995 (update 2002). Management Segment (Chapter 7): Updated 2004 from the 2003 document. Downloaded from www.ginasthma.org

  4. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma.Chest 2001; 119: 1533–1546.

    Article  PubMed  CAS  Google Scholar 

  5. Sarau HM, Ames RS, Chambers Jet al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.Mol Pharmacol 1999; 56: 657–663.

    PubMed  CAS  Google Scholar 

  6. Bisgaard H, Groth S, Madsen F. Bronchial hyperreactivity to leukotriene D4 and histamine in exogenous asthma.Br Med J 1985; 290: 1468–1471.

    Article  CAS  Google Scholar 

  7. Bisgaard H, Olsson P, Bende M. Effects of leukotriene D4 on nasal mucosal blood flow, nasal, airway resistance and nasal secretion in humans.Clin Allergy 1986; 16: 289–297.

    Article  PubMed  CAS  Google Scholar 

  8. Spada CS, Nieves AL, Krauss AH-P, Woodward DF. Comparison of leukotriene B4 and D4 effects of human eosinophils and neutrophil motilityin vitro.J Leukoc Biol 1994; 55: 183–191.

    PubMed  CAS  Google Scholar 

  9. Christie PE, Barnes NC. Leukotriene B4 and asthma.Thorax 1996; 51: 1171–1173.

    PubMed  CAS  Google Scholar 

  10. Cheng H, Leff JA, Amin Ret al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.Pharm Res 1996; 13: 445–448.

    Article  PubMed  CAS  Google Scholar 

  11. Knorr B, Larson P, Nguyen HHet al. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults.J Clin Pharmacol 1999; 39: 786–793.

    Article  PubMed  CAS  Google Scholar 

  12. Knorr B, Nguyen HH, Kearns GLet al. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults.J Clin Pharmacol 2001; 41: 612–619.

    Article  PubMed  CAS  Google Scholar 

  13. Zhao JJ, Rogers JD, Holland SDet al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.Biopharm Drug Dispos 1997; 18: 769–777.

    Article  PubMed  CAS  Google Scholar 

  14. Chiba M, Xu X, Nishime JA, Balani SK, Lin JH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans.Drug Metab Dispos 1997; 25: 1022–1031.

    PubMed  CAS  Google Scholar 

  15. Balani SK, Xu X, Pratha Vet al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.Drug Metab Dispos 1997; 25: 1282–1287.

    PubMed  CAS  Google Scholar 

  16. Skoner D. Montelukast in 2- to 5-year-old children with asthma.Pediatr Pulmonol Suppl 2001; 21: 46–48.

    Article  PubMed  CAS  Google Scholar 

  17. Migoya E, Kearns GL, Hartford Aet al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old.J Clin Pharmacol 2004; 44: 487–494.

    Article  PubMed  CAS  Google Scholar 

  18. Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast.Chest 1998; 114: 332–334.

    Article  PubMed  CAS  Google Scholar 

  19. Straub DA, Moeller A, Minocchieri Set al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma.Eur Respir J 2005; 25: 289–294.

    Article  PubMed  CAS  Google Scholar 

  20. Bisgaard H, Zielen S, Garcia-Garcia MLet al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.Am J Respir Crit Care Med 2005; 171: 315–322.

    Article  PubMed  Google Scholar 

  21. Van Adelsberg J, Moy J, Wei LXet al. Safety, tolerability, and exploratory efficacy of montelukast in 6 to 24 month-old patients with asthma.Curr Med Res & Opin 2005; 21: 971–979.

    Article  CAS  Google Scholar 

  22. Becker A, Swern A, Tozzi CA, Yu Q, Reiss T, Knorr B. Montelukast in asthmatic patients 6 years-14 years old with an FEV1>75%.Curr Med Res Opin 2004; 20: 1651–1659.

    Article  PubMed  CAS  Google Scholar 

  23. Phipatanakul W, Greene C, Downes SJet al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids.Ann Allergy Asthma Immunol 2003; 91: 49–54.

    PubMed  CAS  Google Scholar 

  24. Strauch E, Moske O, Thoma Set al. A randomized controlled trial on the effect of montelukast on sputum eosinophils cationic protein in children with corticosteroid-dependent asthma.Pediatr Res 2003; 54: 198–203.

    Article  PubMed  CAS  Google Scholar 

  25. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor, (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma.J Allergy Clin Immunol 2002; 109: 257–263.

    Article  PubMed  CAS  Google Scholar 

  26. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PAet al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children.J Allergy Clin Immunol 2002; 109: 794–799.

    Article  PubMed  CAS  Google Scholar 

  27. Knorr B, Franchi LM, Bisgaard Het al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.Pediatrics 2001; 108: E48.

    Article  PubMed  CAS  Google Scholar 

  28. Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool, children.Am J Respir Crit Care Med 2000; 162: 187–190.

    PubMed  CAS  Google Scholar 

  29. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast.Am J Respir Crit Care Med 1999; 160: 1227–1231.

    PubMed  CAS  Google Scholar 

  30. Knorr B, Matz J, Bernstein JAet al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.JAMA 1998; 279: 1181–1186.

    Article  PubMed  CAS  Google Scholar 

  31. Stelmach I, Bobrowska-Korzeniowska M, Majak P, Stelmach W, Kuna P. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma.Pulm Pharmacol Ther 2005; 18: 374–380.

    Article  PubMed  CAS  Google Scholar 

  32. Szefler SJ, Phillips BR, Martinez FDet al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.J Allergy Clin Immunol 2005; 115: 233–242.

    Article  PubMed  CAS  Google Scholar 

  33. Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast compared with fluticasone, control of asthma among 6 to 14 year old patients with mild asthma: The MOSAIC study.Pediatrics 2005; 116: 360–369.

    Article  Google Scholar 

  34. Karaman O, Sunneli L, Uzuner Net al. Evaluation of montelukast in 8–14 year old children with mild persistent asthma and compared with inhaled corticosteroids.Allergy Immunopathol (Madr) 2004; 32: 21–27.

    Article  CAS  Google Scholar 

  35. Bukstein DA, Luskin AT, Bernstein A. Real world effectiveness of daily controller medicine in children with mild persistent asthma.Ann Allergy Asthma Immunol 2003; 90: 543–549.

    PubMed  Google Scholar 

  36. Buchvald F, Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide.Ann Allergy Asthma Immunol 2003; 91: 309–313.

    Article  PubMed  CAS  Google Scholar 

  37. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.Cochrane Database Syst Rev 2005; 25: CD003137.

    Google Scholar 

  38. Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate phase and late phase responses.J Allergy Clin Immunol 2003; 111: 301–317.

    Article  PubMed  CAS  Google Scholar 

  39. Peroni DG, Piacentini GL, Ress Met al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children.Pediatr Allergy Immunol 2002; 13: 434–437.

    Article  PubMed  Google Scholar 

  40. Payaron-Fernandez H, Garcia-Rubiaet al. Montelukast administered in the morning or in the evening to prevent exercise induced bronchoconstriction in children.Pediatric Pulmonol 2006; 41: 222–227.

    Article  Google Scholar 

  41. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma.Am J Respir Crit Care Med 2003; 167: 528–533.

    Article  PubMed  Google Scholar 

  42. Kupczyk M, Kuprys I, Gorski P, Kuna P. The effect of montelukast (10mg daily) and loratadine (10mg daily) on wheal, flare and itching reactions in skin prick tests.Pulm Pharmacol Ther 2006 Mar 2 (In press)

  43. Mucha SM, deTineo M, Naclerio RM, Baroody FM. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis.Arch Otolaryngol Head Neck Surg 2006; 132: 164–172.

    Article  PubMed  Google Scholar 

  44. Chen ST, Lu KH, Sun HL, Chang WT, Lue KH, Chou MC. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2–6 yr.Pediatr Allergy Immunol 2006; 17: 49–54.

    Article  PubMed  Google Scholar 

  45. Van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-monty-old patients with asthma.Curr Med Res Opin 2005; 21: 971–979.

    Article  PubMed  CAS  Google Scholar 

  46. Migoya E, Kearns GL, Hartford A, Zhao J, van Adelsberg J, Tozzi CA, Knorr B, Deutsch P. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old.J Clin Pharmacol 2004; 44: 487–494.

    Article  PubMed  CAS  Google Scholar 

  47. Bisgaard H. Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis.J Respir Crit Care Med 2003; 167: 379–383.

    Article  Google Scholar 

  48. Peters-Golden M, Henderson WR Jr. The role of leukotrienes in allergic rhinitis.Ann Allergy Asthma Immunol 2005; 94: 609–618.

    PubMed  CAS  Google Scholar 

  49. Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria.Arch Dermatol Res 2005; 26: 1–5.

    Google Scholar 

  50. Stelmach I, Korzeniewska A, Smejda K, Jarosz I, Stelmach W. Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis.Pneumonol Alergol Pol 2004; 72: 85–89.

    PubMed  Google Scholar 

  51. Brandes JL, Visser WH, Farmer MVet al. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.Headache 2004; 44: 581–586.

    Article  PubMed  Google Scholar 

  52. Quack I, Sellin L, Buchner NJ, Theegarten D, Rump LC, Henning BF. Eosinophilic gastroenteritis in a young girl-long term remission under montelukast.BMC Gastroenterol 2005; 18: 24.

    Article  Google Scholar 

  53. Lambiase A, Bonini S, Rasi G, Coassin M, Bruscolini A, Bonini S. Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma.Arch Ophthalmol 2003; 121: 615–620.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, All India Institute of Medical Sciences, 110029, New Delhi, India

    Mandeep Walia, Rakesh Lodha & S. K. Kabra

Authors
  1. Mandeep Walia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rakesh Lodha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. K. Kabra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. K. Kabra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walia, M., Lodha, R. & Kabra, S.K. Montelukast in pediatric asthma management. Indian J Pediatr 73, 275–282 (2006). https://doi.org/10.1007/BF02825818

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02825818

Key words

Search

Navigation